Georges Chamoun, DO
Gynecologic Oncology · Scranton, PANPI 1558552521
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $48,544 of the $62,578 with a category attached, or 77.6%. Covidien LP accounts for 67.0% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2020 at $27,951 and has fallen 97.2% since, to $794 in 2025.
Across 163 payments — averaging $383.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$42K
- Medtronic$16K
- AstraZeneca$1K
- Johnson & Johnson$1K
- Intuitive Surgical$1K
- Merck$292
- plus $969 from 11 others
What the payments were for
- Consulting fees$48,54478%
- Travel & lodging$8,99414%
- Food & beverage$5,0408%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covidien LP | 18 | $41,923 |
| Medtronic | 20 | $15,758 |
| AstraZeneca | 44 | $1,332 |
| Johnson & Johnson | 14 | $1,232 |
| Intuitive Surgical | 7 | $1,073 |
| Merck | 15 | $292 |
| Myriad Genetic Laboratories, Inc. | 12 | $263 |
| Eisai Inc. | 7 | $142 |
| Smith+Nephew | 8 | $130 |
| Foundation Medicine, Inc. | 5 | $107 |
| GSK | 1 | $97 |
| Medical Device Business Services, Inc. | 3 | $58 |
| Genentech USA, Inc. | 3 | $50 |
| Clovis Oncology, Inc. | 3 | $48 |
| Genmab U.S., Inc. | 1 | $28 |
| Davol Inc. | 1 | $25 |
| Caris MPI, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$907
- ETHICON$595
- LYNPARZA$518
- STRATAFIX$511
- Enseal$472
- VISTASEAL$278
- Harmonic$266
- ECHELON ENDOPATH$238
- SURGIFLO Hemostatic Matrix$227
- Enseal X1$116
- PDS$101
- SURGICEL NU-KNIT$100
How this compares
$62,578 in reported general payments places this provider in the 85th percentile of 90 gynecologic oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 51 | $247 |
| Metronidazole | 36 | $242 |
| Ibuprofen | 33 | $183 |
| Levofloxacin | 33 | $140 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Scranton
- Thomas KrivakPittsburgh$1.6M
- Mark ShahinHershey$914K
- Joshua KestersonNewport$839K
- Charles DuntonWynnewood$309K
- M ThomasAllentown$257K
- Alexander OlawaiyePittsburgh$226K
- John NakayamaPittsburgh$194K
- Emily KoPhiladelphia$78K
- Anna SmithPhiladelphia$77K
- Robert BurgerPhiladelphia$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.